vasculartargeting agent prodrug nacetylcolchinol related shown promising results tumors phase clinical trial identified gastrointestinal cardiac effects limiting two phase ii clinical trials suspended investigating metastatic renal cell carcinoma metastatic colorectal investigated astrazeneca vascular disrupting agent vda however trials halted became apparent cardiotoxic required antineoplastic immunomodulatory drug article stub help wikipedia expanding